Literature DB >> 25828146

Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment.

Wei Pan1, Qian Sun, Yang Wang, Jian Wang, Shui Cao, Xiubao Ren.   

Abstract

The hallmark of tumor microenvironment is that it makes up of numerous immunomodulatory cells and factors which exert essential roles in immunoprotection and immunosuppression in addition to tumor cells. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells reported to promote immunosuppression and angiogenesis and facilitate tumor metastasis and invasion. The wide scope of MDSCs functional activities make these cells promising targets for effective cancer treatments. In this review, we briefly discuss the origin, subpopulation, and functions of MDSCs, as well as the potential to target these cells for therapeutic benefit. We focus on the underlying molecular mechanisms of these drugs targeting MDSCs, mainly from the standpoint of molecules related to drug targets.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25828146     DOI: 10.1007/s13277-015-3363-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  107 in total

1.  Ras signaling enhances the activity of C/EBP alpha to induce granulocytic differentiation by phosphorylation of serine 248.

Authors:  Gerhard Behre; Sheo M Singh; Huaitian Liu; Laura T Bortolin; Max Christopeit; Hanna S Radomska; Janki Rangatia; Wolfgang Hiddemann; Alan D Friedman; Daniel G Tenen
Journal:  J Biol Chem       Date:  2002-04-26       Impact factor: 5.157

2.  Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4.

Authors:  Johanna M Ketolainen; Emma-Leena Alarmo; Vilppu J Tuominen; Anne Kallioniemi
Journal:  Breast Cancer Res Treat       Date:  2010-02-25       Impact factor: 4.872

3.  Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL.

Authors:  Pratima Sinha; Olesya Chornoguz; Virginia K Clements; Konstantin A Artemenko; Roman A Zubarev; Suzanne Ostrand-Rosenberg
Journal:  Blood       Date:  2011-03-30       Impact factor: 22.113

Review 4.  The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.

Authors:  Je-In Youn; Dmitry I Gabrilovich
Journal:  Eur J Immunol       Date:  2010-11       Impact factor: 5.532

5.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

6.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Authors:  Junko Ozao-Choy; Ge Ma; Johnny Kao; George X Wang; Marcia Meseck; Max Sung; Myron Schwartz; Celia M Divino; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

7.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

8.  Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice.

Authors:  Maciej Kujawski; Marcin Kortylewski; Heehyoung Lee; Andreas Herrmann; Heidi Kay; Hua Yu
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

9.  Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.

Authors:  Minu K Srivastava; Jacobus J Bosch; James A Thompson; Bruce R Ksander; Martin J Edelman; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Immunother       Date:  2008-03-06       Impact factor: 6.968

10.  Does BRAF Mutation and Extracellular Signal Regulated Kinase Expression in Patients With Colorectal Cancer Have Any Prognostic Significance?

Authors:  Moo Jun Baek
Journal:  Ann Coloproctol       Date:  2015-02
View more
  5 in total

Review 1.  The immunobiology of myeloid-derived suppressor cells in cancer.

Authors:  Morteza Motallebnezhad; Farhad Jadidi-Niaragh; Elmira Safaie Qamsari; Salman Bagheri; Tohid Gharibi; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2015-11-26

2.  Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model.

Authors:  Xiang Huang; Shiyun Cui; Yongqian Shu
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

Review 3.  The Role of Myeloid-Derived Suppressor Cells in Viral Infection.

Authors:  Megan A O'Connor; Jessica L Rastad; William R Green
Journal:  Viral Immunol       Date:  2017-01-04       Impact factor: 2.257

Review 4.  Synergy Between Low Dose Metronomic Chemotherapy and the pH-centered Approach Against Cancer.

Authors:  Tomas Koltai; Rosa A Cardone; Stephan J Reshkin
Journal:  Int J Mol Sci       Date:  2019-10-31       Impact factor: 5.923

Review 5.  Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.

Authors:  Viktor Fleming; Xiaoying Hu; Rebekka Weber; Vasyl Nagibin; Christopher Groth; Peter Altevogt; Jochen Utikal; Viktor Umansky
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.